| Publications | PubMed=19449367; DOI=10.1002/path.2564
Snyder E.L., Sandstrom D.J., Law K., Fiore C., Sicinska E.T., Brito J., Bailey D., Fletcher J.A., Loda M., Rodig S.J., Dal Cin P.S., Fletcher C.D.M.
c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme.
J. Pathol. 218:292-300(2009) PubMed=19706776; DOI=10.1158/0008-5472.CAN-08-4004
Muhlenberg T., Zhang Y.-X., Wagner A.J., Grabellus F., Bradner J., Taeger G., Lang H., Taguchi T., Schuler M., Fletcher J.A., Bauer S.
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.
Cancer Res. 69:6941-6950(2009) PubMed=20713527; DOI=10.1158/0008-5472.CAN-10-0745
Brill E.R., Gobble R.M., Angeles C.V., Lagos-Quintana M., Crago A., Laxa B.U., DeCarolis P.L., Zhang L., Antonescu C.R., Socci N.D., Taylor B.S., Sander C., Koff A., Singer S.
ZIC1 overexpression is oncogenic in liposarcoma.
Cancer Res. 70:6891-6901(2010) PubMed=21335544; DOI=10.1158/0008-5472.CAN-10-3588
Gobble R.M., Qin L.-X., Brill E.R., Angeles C.V., Ugras S., O'Connor R.B., Moraco N.H., DeCarolis P.L., Antonescu C.R., Singer S.
Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis.
Cancer Res. 71:2697-2705(2011) PubMed=21693658; DOI=10.1158/0008-5472.CAN-11-0890
Ugras S., Brill E.R., Jacobsen A., Hafner M., Socci N.D., DeCarolis P.L., Khanin R., O'Connor R.B., Mihailovic A., Taylor B.S., Sheridan R., Gimble J.M., Viale A.J., Crago A., Antonescu C.R., Sander C., Tuschl T., Singer S.
Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma.
Cancer Res. 71:5659-5669(2011) PubMed=22328974; DOI=10.1158/2159-8290.CD-11-0181
Taylor B.S., DeCarolis P.L., Angeles C.V., Brenet F., Schultz N., Antonescu C.R., Scandura J.M., Sander C., Viale A.J., Socci N.D., Singer S.
Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas.
Cancer Discov. 1:587-597(2011) PubMed=22170698; DOI=10.1002/gcc.21917
Wu Y.V., Okada T., DeCarolis P.L., Socci N.D., O'Connor R.B., Geha R.C., Somberg C.J., Antonescu C.R., Singer S.
Restoration of C/EBPalpha in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis.
Genes Chromosomes Cancer 51:313-327(2012) PubMed=22911243; DOI=10.1155/2012/148614
Stratford E.W., Castro R., Daffinrud J., Skarn M., Lauvrak S., Munthe E., Myklebost O.
Characterization of liposarcoma cell lines for preclinical and biological studies.
Sarcoma 2012:148614.1-148614.9(2012) PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015) PubMed=26643872; DOI=10.18632/oncotarget.6464
Kanojia D., Nagata Y., Garg M., Lee D.H., Sato A., Yoshida K., Sato Y., Sanada M., Mayakonda A., Bartenhagen C., Klein H.-U., Doan N.B., Said J.W., Mohith S., Gunasekar S., Shiraishi Y., Chiba K., Tanaka H., Miyano S., Myklebost O., Yang H., Dugas M., Meza-Zepeda L.A., Silberman A.W., Forscher C., Tyner J.W., Ogawa S., Koeffler H.P.
Genomic landscape of liposarcoma.
Oncotarget 6:42429-42444(2015) |
|---|